Technical Event
Pascal Rol Keynote Address
25 January 2025 • 1:30 PM - 2:30 PM PST | Moscone South, Room 156 (Upper Mezz)
The Pascal Rol keynote presentation was established to promote the exchange of ideas between clinicians with a technological need and engineers interested in solving problems in ophthalmology. The invited lecture is sponsored by the Pascal Rol Foundation.
1:30 PM - 1:35 PM: Introduction
Per Söderberg, Uppsala Univ. (Sweden)
1:35 PM - 2:30 PM: Structural and functional biomarkers for glaucoma neuroprotection trials
Jeffrey Goldberg, Byers Eye Institute, Stanford Univ. (United States)
Pascal Rol Keynote Address: Glaucoma is a common neurodegenerative disease associated with progressive axon degeneration and cell death of retinal ganglion cells (RGCs). Here we will review recent steps forward revealing the pathophysiology of RGC degeneration, and the therapeutic targets to promote RGC neuroprotection and regeneration. Translating these advances from lab-based research in animal models, into human clinical trials with patients, has begun in earnest, but will likely rely on development of additional biomarkers for measuring relevant structural and functional outcomes in disease and its treatment. We will discuss recent data from the lab on advances in measuring RGC function in animal models in vivo, and in non-invasively measuring RGC structure, function, and metabolism in human patients.
Dr. Jeffrey Goldberg is Professor and Chair of Ophthalmology and Director of the Byers Eye Institute at Stanford University, and a member of the National Academy of Medicine. His research is directed at neuroprotection and regeneration of retinal ganglion cells and the optic nerve, a major unmet need in glaucoma and other optic neuropathies, and his laboratory is developing novel molecular, stem cell and nanotherapeutics approaches for eye repair.
Dr. Goldberg received his B.S. magna cum laude from Yale, his M.D. and Ph.D. from Stanford, and his clinical training in ophthalmology and then glaucoma at the Bascom Palmer Eye Institute, with a Heed fellowship. He was the Hope For Vision foundation's 2010 Scientist of the Year, and ARVO's 2012 Cogan awardee. He was elected in 2010 to the American Society of Clinical Investigation, and in 2021 to the American Ophthalmological Society.
MENU: Coffee, decaf, and tea will be available outside the presentation room.
SETUP: Theater style seating.
1:30 PM - 1:35 PM: Introduction
Per Söderberg, Uppsala Univ. (Sweden)
1:35 PM - 2:30 PM: Structural and functional biomarkers for glaucoma neuroprotection trials
Jeffrey Goldberg, Byers Eye Institute, Stanford Univ. (United States)
Pascal Rol Keynote Address: Glaucoma is a common neurodegenerative disease associated with progressive axon degeneration and cell death of retinal ganglion cells (RGCs). Here we will review recent steps forward revealing the pathophysiology of RGC degeneration, and the therapeutic targets to promote RGC neuroprotection and regeneration. Translating these advances from lab-based research in animal models, into human clinical trials with patients, has begun in earnest, but will likely rely on development of additional biomarkers for measuring relevant structural and functional outcomes in disease and its treatment. We will discuss recent data from the lab on advances in measuring RGC function in animal models in vivo, and in non-invasively measuring RGC structure, function, and metabolism in human patients.
Dr. Jeffrey Goldberg is Professor and Chair of Ophthalmology and Director of the Byers Eye Institute at Stanford University, and a member of the National Academy of Medicine. His research is directed at neuroprotection and regeneration of retinal ganglion cells and the optic nerve, a major unmet need in glaucoma and other optic neuropathies, and his laboratory is developing novel molecular, stem cell and nanotherapeutics approaches for eye repair.
Dr. Goldberg received his B.S. magna cum laude from Yale, his M.D. and Ph.D. from Stanford, and his clinical training in ophthalmology and then glaucoma at the Bascom Palmer Eye Institute, with a Heed fellowship. He was the Hope For Vision foundation's 2010 Scientist of the Year, and ARVO's 2012 Cogan awardee. He was elected in 2010 to the American Society of Clinical Investigation, and in 2021 to the American Ophthalmological Society.
Event Details
FORMAT: General session with live audience Q&A to follow each presentation.MENU: Coffee, decaf, and tea will be available outside the presentation room.
SETUP: Theater style seating.